The latest price target for Cytokinetics (NASDAQ:CYTK) was reported by Morgan Stanley on February 13, 2025. The analyst firm set a price target for $67.00 expecting CYTK to rise to within 12 months (a possible 31.37% upside). 65 analyst firms have reported ratings in the last year.

The latest analyst rating for Cytokinetics (NASDAQ:CYTK) was provided by Morgan Stanley, and Cytokinetics upgraded their overweight rating.

The last upgrade for Cytokinetics Inc happened on February 13, 2025 when Morgan Stanley raised their price target to $67. Morgan Stanley previously had an equal-weight for Cytokinetics Inc.

The last downgrade for Cytokinetics Inc happened on August 13, 2024 when Goldman Sachs changed their price target from $85 to $60 for Cytokinetics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytokinetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytokinetics was filed on February 13, 2025 so you should expect the next rating to be made available sometime around February 13, 2026.

While ratings are subjective and will change, the latest Cytokinetics (CYTK) rating was a upgraded with a price target of $70.00 to $67.00. The current price Cytokinetics (CYTK) is trading at is $51.00, which is out of the analyst’s predicted range.